Chemistry/Immunology Reagents/Analyzer
Overview
- Response deadline
- 11:00 AM HST
- Posted
- November 19, 2026
- Notice type
- Special Notice
- Set-aside
- No Set aside used
- Agency
- Department of WarDEFENSE HEALTH AGENCY (DHA)
Notice details
- Office
- DEFENSE HEALTH AGENCY HCD WEST
- Last updated
- Nov 19, 2026
- First published
- Last updated on SAM.gov
Identifiers
- Solicitation number
- HT941027N0014
- Notice ID
- bf19497f9cfc4dc4855e9bbc6a1848ae
Description
Notice of Intent to Sole Source
HT941027N0014
THIS IS A NOTICE OF INTENT TO AWARD A SOLE SOURCE PURCHASE ORDER CONTRACT AND IS NOT A REQUEST FOR COMPETITIVE QUOTES.
The Defense Health Agency Contracting Activity (DHACA), Healthcare Contracting Division – San Diego (HCD-SD), Echo Branch intends to award a firm fixed price five (5)-Year Purchase order RFO 12.102 (b) for acquisitions valued over the SAT, only one source being available to meet the Government’s needs, to:
ORTHO CLINICAL DIAGNOSTICS SINGAPORE PTE LTD, KOREA BRANCH
366 HANGANG-DAERO
YONGSAN-GU, SEOUL, 04323 SOUTH KOREA
UEI: JNSJRDQQH2J6
CAGE: 767DF
The North American Industry Classification System (NAICS) code for this requirement is 325413 - Pharmaceutical Preparation Manufacturing; the business size standard is 1,250 (in number of employees). The Product Service Code (PSC) is 6550 – Invitro Diagnostics Substances Reagents
The objective of this sole source award is to procure Chemistry/Immunology Reagents with Analyzer for Brian D. Allgood Army Community Hospital, South Korea for the Department of Pathology.
The contractor-furnished chemistry and immunology analyzers shall be capable of providing complete chemistry and immunochemistry testing. The entire analyzer system shall be serviced and supplied through a single Contractor awarded the contract, including all parts, equipment, and supplies not manufactured, provided, or serviced directly by the Contractor.
The system shall provide redundancy to ensure continuous operations. Each analyzer shall have the capacity to perform both chemistry and immunology assays. The Contractor shall provide the system, training, supplies, reagents, unscheduled maintenance, and preventive maintenance. All equipment displays and supporting literature shall be in English.
The Contractor shall include delivery, installation, all calibrators and standards, reagents and reagent packs, and quality-control materials necessary to perform the specified assays. The Contractor shall also perform initial method validations in accordance with Clinical and Laboratory Standards Institute (CLSI) guidelines. The Contractor shall remove the analyzers upon contract termination.
Rationale Justifying:
Ortho Clinical Diagnostics Singapore Pte. Ltd., Korea Branch, a division of QuidelOrtho Corporation, is the sole manufacturer capable of providing clinical chemistry and integrated chemistry/immunoassay analyzers that meet the Government’s test-volume requirements without requiring a facility water supply.
The Defense Health Agency requires analyzers that use 100 percent waterless, dry-slide technology. These sites cannot receive reagent-grade water into the facility for safe, quality laboratory testing and are not approved by the state to discharge biohazardous waste into any drain. This technology is unique to QuidelOrtho’s VITROS® line of analyzers and is essential to meeting the agency’s operational and mission requirements for the following reasons:
Infrastructure Independence: VITROS dry-slide technology eliminates the need for water, plumbing, and drains. This is a critical advantage in military healthcare environments, where logistical footprints must be minimized. It ensures operational continuity and significantly reduces infrastructure dependencies.
Enhanced Quality and Reliability: The system uses disposable tips for each sample, eliminating the risk of sample-to-sample carryover and reagent-to-reagent contamination that can occur in traditional wet-chemistry systems. This supports the accuracy and reliability of test results for patient care, particularly for high-acuity, time-sensitive assays.
For example, emergency physicians rely on rapid, accurate first-run results for high-sensitivity troponin to triage potential heart attacks; procalcitonin and lactic acid to diagnose life-threatening sepsis; and potassium levels to treat sudden acute renal or metabolic failure. In these life-threatening situations, a false or contaminated initial result can delay critical medical intervention. The dry-slide technology’s elimination of sample carryover helps ensure that providers can rely on the initial result when time is of the essence.
Laboratory Productivity: Reagents are self-contained in a dry-slide format that provides calibration stability of up to six months for most assays. This extended calibration interval substantially reduces the time and labor associated with daily calibration and quality-control procedures while also reducing reagent waste.systems. This ensures the highest accuracy and reliability of test results for patient care, which is absolutely critical for high-acuity, time-sensitive assays. For example, emergency physicians rely on rapid, flawless first-time results for high sensitivity troponin to triage imminent heart attacks, procalcitonin and lactic acid to diagnose life-threatening sepsis, and potassium levels to treat sudden acute renal or metabolic failure. In these life-or-death scenarios, a false or contaminated first read delays vital medical interventions; the dry-slide technology's elimination of sample carryover ensures providers can trust the initial result when time is of the essence. Laboratory Productivity: Reagents are self-contained in a dry-slide format that provides up to a six-month calibration stability for most assays. This extended frequency drastically reduces the time and labor spent on daily calibration and quality control procedures while decreasing reagent waste.
Product List:
Chemistry/Immunology Annual Test Count
Test Base Year 6-Month Option Year I Option Year II Option Year III Option Year IV
1 ACETAMINOPHEN 1,541 1,731 1,783 1,836 1,891
2 ALBUMIN 9,202 17,513 18,038 18,579 19,136
3 ALANINE AMINOTRANSFERASE 9,209 17,529 18,055 18,597 19,155
4 ALKALINE PHOSPHATASE 9,285 17,684 18,215 18,762 19,325
5 AMYLASE 1,470 1,586 1,634 1,683 1,734
6 ASPARTATE AMINOTRANSFERASE 9,914 18,980 19,549 20,136 20,740
7 BILIRUBIN TOTAL 9,581 18,295 18,844 19,409 19,991
8 BILIRUBIN DIRECT 1,343 2,088 2,151 2,216 2,283
9 BILIRUBIN CONJUGATED 662 1,003 1,033 1,064 1,096
10 BILIRUBIN UNCONJUGATED 662 1,003 1,033 1,064 1,096
11 BILIRUBIN NEONATAL 85 132 136 140 144
12 CALCIUM 9,642 18,420 18,973 19,542 20,128
13 CARBON DIOXIDE 9,626 18,387 18,939 19,507 20,092
14 CHLORIDE 9,771 18,686 19,247 19,824 20,419
15 CHOLESTEROL TOTAL 4,951 8,757 9,020 9,291 9,570
16 CK-MB 1,992 2,660 2,740 2,822 2,907
17 C-REACTIVE PROTEIN 2,349 3,396 3,498 3,603 3,711
18 CREATININE 10,084 19,360 19,941 20,539 21,155
19 CREATININE, RANDOM URINE 206 396 408 420 433
20 CREATINE KINASE 1,993 2,663 2,743 2,825 2,910
21 ETHANOL 2,674 4,065 4,187 4,313 4,442
22 G-GLUTAMYL TRANSFERASE 2,195 3,079 3,171 3,266 3,364
23 GENTAMICIN PEAK 834 579 596 614 632
24 GENTAMICIN TROUGH 222 154 159 164 169
25 GLUCOSE 10,228 19,784 20,378 20,989 21,619
26 GLUCOSE 1ST 46 89 92 95 98
27 GLUCOSE 2ND 46 89 92 95 98
28 GLUCOSE 3RD 46 89 92 95 98
29 GLUCOSE POSTPRANDIAL 3 4 4 4 4
30 GLUCOSE POST 50G GLUCOLA 1H 149 288 297 306 315
31 GLUCOSE POST 75G GLUCOLA 2H 12 23 24 25 26
32 GLUCOSE FASTING 918 1,775 1,828 1,883 1,940
33 GLUCOSE CSF 23 44 45 46 47
34 HDL CHOLESTEROL 4,879 8,609 8,867 9,133 9,407
35 IRON 1,465 1,575 1,622 1,671 1,721
36 LACTATE 1,647 1,951 2,010 2,070 2,132
37 LACTATE DEHYDROGENASE 1,476 1,598 1,646 1,695 1,746
38 LIPASE 2,637 3,990 4,110 4,233 4,360
39 MAGNESIUM 2,103 2,889 2,976 3,065 3,157
40 PHOSPHORUS 1,823 2,312 2,381 2,452 2,526
41 POTASSIUM 10,047 19,254 19,832 20,427 21,040
42 PROTEIN 9,075 17,253 17,771 18,304 18,853
43 PROTEIN CSF 847 303 312 321 331
44 PROTEIN, RANDOM URINE 1,184 996 1,026 1,057 1,089
45 SALICYLATES 1,520 1,689 1,740 1,792 1,846
46 SODIUM 10,568 20,327 20,937 21,565 22,212
47 TRIGLYCERIDE 4,983 8,822 9,087 9,360 9,641
48 UREA NITROGEN 9,808 18,761 19,324 19,904 20,501
49 URIC ACID 1,556 1,762 1,815 1,870 1,926
50 VANCOMYCIN PEAK 574 446 459 473 487
51 VANCOMYCIN TROUGH 551 429 442 455 469
52 HCG QN 2,628 3,972 4,091 4,214 4,340
53 THYROTROPIN 5,327 9,531 9,817 10,112 10,415
54 T4 FREE 2,318 3,332 3,432 3,535 3,641
55 THYROXINE, TOTAL 1,950 2,575 2,652 2,732 2,814
56 TROPONIN I CARDIAC 2,855 4,438 4,571 4,708 4,849
57 HEPATITIS B SURFACE AG 3,435 5,633 5,802 5,976 6,155
58 HEPATITIS B SURFACE AB 3,848 6,485 6,680 6,880 7,086
59 HEPATITIS B CORE AB TOTAL 3,522 5,183 5,339 5,500 5,665
60 HEPATITIS C AB 3,193 5,136 5,290 5,449 5,613
61 HEPATITIS A IGM 2,675 4,068 4,190 4,316 4,446
62 HEPATITIS A AB, TOTAL 2,964 4,663 4,803 4,947 5,095
63 RUBELLA VIRUS IGG 1,724 2,108 2,171 2,236 2,303
64 HBA1C-IFCC, NGSP 4,668 8,173 8,418 8,671 8,931
65 PRO-BNP 2,322 3,341 3,441 3,544 3,650
Agency and Requirement Description and Market Research Conducted:
DHA HCD-SD is supporting Brian D. Allgood Army Community Hospital in South Korea, with a requirement for Chemistry/Immunology Reagents with Analyzer. Specifically, this requirement is for tests in the product list above.
Extensive market research through the General Services Administration (GSA), Federal Supply Schedules (FSS), or other mandatory sources. Broad database searches were conducted across FPDS-NG, GSA Advantage, GSA eLibrary, GSA Global Supply, NASA SEWP, and VA FSS using keywords such as “Chemistry”. These searches either yielded zero results or failed to identify contractors capable of providing the exact or equal supplies required. Additionally, a review of internal contracting activity via the BPA Tracker revealed no similar contracts currently in place to leverage. Open market research, including internet searches and personal telephone contacts with potential vendors, confirmed that while "Chemistry/Immunology Reagents/Analyzers" are commercially available RFO 12.102(b) only Ortho Clinical Diagnostics Singapore PTE LTD, Korea Branch is the only vendor that can meet the agency's requirements.
Delivery location:
BRIAN D. ALLGOOD ARMY COMMUNITY HOSPITAL
348TH QM CO SRA BLDG
1603 CAMP HUMPHREYS PYEONGTAEK, 17982
Estimated Delivery Schedule: 1 April 2027 to 30 September 2031 (Including a 6 month base period and four (4) 12 month option years).
Based on market research and previous acquisition history, it has been determined that Ortho Clinical Diagnostics Singapore PTE LTD, Korea Branch, is the only source that can meet the Government’s minimum requirements to provide chemistry/immunology reagents and analyzer for the Brian D. Allgood Army Community Hospital.
This notice of intent is not a request for competitive proposals, and no solicitation document exists for this requirement. Sources interested in responding to this notice are required to submit a capability statement that includes management and technical data and cost information, in sufficient detail and with convincing evidence that clearly demonstrates the capability to provide the chemistry/immunology reagents and analyzer for the Brian D. Allgood Army Community Hospital. Capability statements shall not exceed two (2) (8.5 x 11 inch) pages using a font size no smaller than 10-point. All capability statements received by the due date of this notice will be considered by the Government. A request for documentation or additional information or submissions that only ask questions will not be considered as an affirmative response. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement or to proceed with a sole source purchase order.
If a vendor challenges the basis of this requirement, please email capability statements as a Microsoft Word or Adobe PDF attachment to Contract Specialist Susan Fujita at susan.m.fujita.civ@health.mil and Contracting Officer Cha-on P. Gordon at cha-on.p.gordon2.civ@health.mil. The closing date for challenges is no later than 11:00 a.m. (Hawaii Time), Thursday December 3, 2026.
NO TELEPHONE REQUESTS/OFFERS WILL BE HONORED.
Award Overview
No prior contract identified
No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.
Contacts
Contracting Officer
Primary Contact
Documents
No documents available.
Lifecycle
- 1Version 1Special NoticeCurrent
Chemistry/Immunology Reagents/Analyzer
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
Additional Details
Solicitation Number
HT941027N0014
Archive Date
Dec 4, 2026
Place of Performance Country
KOREA, SOUTH
Office Address
CAMP PENDLETON, CA, 92055